Large Outflow of Money Witnessed in China Biologic Products, Inc.

Shares of China Biologic Products, Inc. (CBPO) traded 0.36 points or 0.32% higher at $114.3.The total intraday money flow for the shares came in at a disappointing $(-2.02) million. The total upticks amounted to $1.65 million and the total downticks were approximately $3.67 million, with the up/down ratio of 0.45. On a different note, the shares have seen 0.72% price change during the week.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

China Biologic Products, Inc. has dropped 0.36% in the last five trading days, however, the shares have posted positive gains of 5.65% in the last 4 weeks. China Biologic Products, Inc. has dropped 3.83% during the last 3-month period . Year-to-Date the stock performance stands at 5.65%. China Biologic Products, Inc. (NASDAQ:CBPO) witnessed a decline in the market cap on Wednesday as its shares dropped 0.31% or 0.35 points. After the session commenced at $113.94, the stock reached the higher end at $115.09 while it hit a low of $112.9. With the volume soaring to 190,037 shares, the last trade was called at $113.59. The company has a 52-week high of $137.385. The company has a market cap of $3,083 million and there are 27,137,825 shares in outstanding. The 52-week low of the share price is $100.53.

Company has reported several Insider transactions to the SEC, on Aug 17, 2016, Zhijing Cbpo Liu (Corporate Vice President) sold 1,968 shares at 124.32 per share price.On Aug 17, 2016, Wenfang Liu (director) sold 2,900 shares at 124.32 per share price.On Aug 17, 2016, Ming Yin (Sr. Corporate Vice President) sold 20,334 shares at 124.32 per share price.

China Biologic Products Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.09. Analyst had a consensus of $1.10. The company had revenue of $86.53 million for the quarter, compared to analysts expectations of $87.89 million. The companys revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.82 EPS.

China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Companys principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.


Share this post

Leave a Reply